Do you want to read an article? Please log in or register.
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
Myeloproliferative Neoplasms (MPNs)
Related content
RECOMMENDED
Breast Cancer
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee
doi: 10.1200/JCO-25-02705
Breast Cancer
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial
Ann Oncol
Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)
doi: 10.1016/j.annonc.2026.05.703
Genitourinary Cancer
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
Lancet Oncol
Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P
doi: 10.1016/S1470-2045(25)00658-8
Lung, Respiratory and Thoracic Cancer
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L
doi: 10.1016/S1470-2045(26)00282-2
Breast Cancer
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy
Ann Oncol
Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G
doi: 10.1016/j.annonc.2026.10.1283
Myeloproliferative Neoplasms (MPNs)
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
Blood Cancer J
Koschmieder S, Isfort S, Teichmann LL, Schafhausen P, Heidel FH, Crodel C, Hochhaus A, Griesshammer M, Sockel K, Jost PJ, Walther D, Döhner K, Göthert JR, Radsak M, Augustin M, Becker H, Giagounidis A, Schaich M, Klausmann M, von Bubnoff N, Stegelmann F, Kortmann M, Zentis M, Frank J, Hagemeier A, Hellmich M, Brümmendorf TH, German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
doi: 10.1038/s41408-026-01644-2
Gastrointestinal Cancer
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol
Tao K, Lin Z, Zhang P, Chi P, Xiao Y, Hou Z, Xu X, Zhang A, Qiu X, Wu J, Yuan Y, Wang Z, Qu X, Li X, Nie X, Yang M, Cai K, Wang Z, Zhang W, Huang Y, Sun Z, Zheng R, Zhao F, Han C, Zhang T
doi: 10.1016/S1470-2045(26)00446-8
Leukemia
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
J Clin Oncol
Pollard JA, Alonzo TA, Gerbing RB, Kutny M, Hirsch B, Raca G, Leger K, Wilkes J, Pabari R, Wadhwa A, Graff Z, Kahwash S, Chisholm K, Chewning J, Horan J, Aplenc R, Place A, Tasian SK, Tarlock K, Menig S, Militano O, Ky B, Hudson C, Loken MR, Menssen A, Brodersen LE, Meshinchi S, Kolb EA, Cooper TM
doi: 10.1200/JCO-25-02979
Breast Cancer
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
Lancet Oncol
Seefat RL, Vliek SB, de Jong VMT, Balduzzi S, Mandjes IA, Retèl VP, Eekhout I, Delfos M, Schot M, Holtkamp MJ, van Rosmalen MM, Leeneman B, Blommestein H, Huitema ADR, Rosenberg EH, Nederlof PM, Chan TWS, van Rhenen A, Wondergem MJ, Schaap NPM, Snijders TJF, Van der Poel MWM, Plattel WJ, van Werkhoven E, van Tinteren H, Smidt ML, Wesseling J, Jonkers J, Rottenberg S, Vrancken Peeters MTFD, Voermans C, Maduro JH, Kroep JR, Schroder CP, Kuip EJM, Gonçalves A, Nuver J, Wymenga ANM, Bijlsma RM, van der Wall E, Konings IRHM, Tjan-Heijnen VCG, Jongen-Lavrencic M, Jager A, Linn SC
doi: 10.1016/S1470-2045(26)00131-2